story of the week
ESMO 2021: Trastuzumab Deruxtecan Beats Trastuzumab Emtansine for HER2-Positive Metastatic Breast Cancer
Findings of DESTINY-Breast03 suggest trastuzumab deruxtecan should be standard of care in the second-line setting
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.